Literature DB >> 20222180

Transporters in drug development: advancing on the Critical Path.

Shiew-Mei Huang1, Janet Woodcock.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20222180     DOI： 10.1038/nrd3124

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  4 in total

1.  Rhabdomyolysis due to interaction of simvastatin with mibefradil.

Authors:  D Schmassmann-Suhijar; R Bullingham; R Gasser; J Schmutz; W E Haefeli
Journal:  Lancet       Date:  1998-06-27       Impact factor: 79.321

Review 2.  Membrane transporters in drug development.

Authors:  Kathleen M Giacomini; Shiew-Mei Huang; Donald J Tweedie; Leslie Z Benet; Kim L R Brouwer; Xiaoyan Chu; Amber Dahlin; Raymond Evers; Volker Fischer; Kathleen M Hillgren; Keith A Hoffmaster; Toshihisa Ishikawa; Dietrich Keppler; Richard B Kim; Caroline A Lee; Mikko Niemi; Joseph W Polli; Yuichi Sugiyama; Peter W Swaan; Joseph A Ware; Stephen H Wright; Sook Wah Yee; Maciej J Zamek-Gliszczynski; Lei Zhang
Journal:  Nat Rev Drug Discov       Date:  2010-03       Impact factor: 84.694

3.  Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States.

Authors:  Dima M Qato; G Caleb Alexander; Rena M Conti; Michael Johnson; Phil Schumm; Stacy Tessler Lindau
Journal:  JAMA       Date:  2008-12-24       Impact factor: 56.272

4.  SLCO1B1 variants and statin-induced myopathy--a genomewide study.

Authors:  E Link; S Parish; J Armitage; L Bowman; S Heath; F Matsuda; I Gut; M Lathrop; R Collins
Journal:  N Engl J Med       Date:  2008-07-23       Impact factor: 91.245
  4 in total
  5 in total

1.  The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions.

Authors:  C Rafaniello; M Sessa; F F Bernardi; M Pozzi; S Cheli; D Cattaneo; S Baldelli; M Molteni; R Bernardini; F Rossi; E Clementi; C Bravaccio; S Radice; A Capuano
Journal:  Pharmacogenomics J       Date:  2017-07-18       Impact factor: 3.550

2.  Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug-Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor Velpatasvir.

Authors:  Erik Mogalian; Polina German; Brian P Kearney; Cheng Yong Yang; Diana Brainard; John McNally; Lisa Moorehead; Anita Mathias
Journal:  Clin Pharmacokinet       Date:  2016-05       Impact factor: 6.447

3.  Transporters in Regulatory Science: Notable Contributions from Dr. Giacomini in the Past Two Decades.

Authors:  Lei Zhang; Qi Liu; Shiew-Mei Huang; Robert Lionberger
Journal:  Drug Metab Dispos       Date:  2022-06-29       Impact factor: 3.579

4.  AAPS workshop report: strategies to address therapeutic protein-drug interactions during clinical development.

Authors:  Sandhya Girish; Steven W Martin; Mark C Peterson; Lei K Zhang; Hong Zhao; Joseph Balthasar; Raymond Evers; Honghui Zhou; Min Zhu; Lewis Klunk; Chao Han; Eva Gil Berglund; Shiew-Mei Huang; Amita Joshi
Journal:  AAPS J       Date:  2011-06-01       Impact factor: 4.009

Review 5.  Membrane transporter data to support kinetically-informed chemical risk assessment using non-animal methods: Scientific and regulatory perspectives.

Authors:  Laure-Alix Clerbaux; Alicia Paini; Annie Lumen; Hanan Osman-Ponchet; Andrew P Worth; Olivier Fardel
Journal:  Environ Int       Date:  2019-03-08       Impact factor: 9.621
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.